Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Location contact
Jonathan Bricker, PhD
CONTACT
Jonathan Bricker, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07739706
This clinical trial compares a novel smartphone application (app) called QuitQuest to the National Cancer Institute's (NCI's) SmokefreeTeenQuitVaping (SFTQV) app in helping teens stop vaping. Despite recent declines, data shows that 8.5% of middle school (grades 6-8) and 18.1% of high school (grades 9-12) students in the United States (US) used electronic nicotine delivery systems (ENDS; variously known as vaping, electronic [e]-cigarettes, e-cigs, mods, and tank systems that contain nicotine). Use of any tobacco product during adolescence increases risk for lifelong nicotine addiction. ENDS use, in particular, leads to severe asthma attacks, e-cigarette or vaping product use-associated lung injury (EVALI), exposure to multiple lung irritants, including volatile organic compounds, and lasting harm to adolescent brain development. Despite evidence of potential long-term harms from ENDS, to date there have been limited evidence-based therapeutic options for ENDS cessation for adolescents and young adults. Traditional methods for delivering adolescent ENDS cessation interventions (e.g., quitlines and clinics) have limited reach. QuitQuest utilizes Acceptance and Commitment Therapy (ACT), a psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility, reduce distress, and promote behavior change through mechanisms that include cultivating acceptance of internal experience and aligning behavior with personal values. The SFTQV program is based on the US Clinical Practice Guidelines, offering practical advice and support via an app delivery format. The QuitQuest app may work better than the SFTQV app in increasing vape quit rates among teens.
Trial opening soon.
Get Notified13 year–17 year
All sexes
Interventional
Not applicable
Seattle, Washington, 98109, United States
Jonathan Bricker, PhD
CONTACT
Jonathan Bricker, PhD
PRINCIPAL_INVESTIGATOR
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants download and install the QuitQuest app for 12 months on study.
ARM II: Participants utilize the National Cancer Institute's (NCI's) SFTQV app for 12 months on study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use QuitQuest app
Other names: Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention
Ancillary studies
Ancillary studies
Time frame: At 6 months post-randomization
Biochemical verification will be used to validate self-reported abstinence among participants who opt in at baseline and complete testing. In the primary intent-to-treat analysis, participants with missing 6-month self-reported outcome data will be classified as vaping. The primary missing=vaping outcome is based on self-reported 30-day ENDS use status, not on completion of biochemical verification. Participants who self-report abstinence but do not complete biochemical testing will not be automatically classified as vaping solely because biochemical verification is missing. The primary logistic regression model will adjust for the stratification factors used in randomization to appropriately account for study design, thereby improving the estimation of standard errors and increasing the validity of significance tests for the main treatment effect.
Time frame: At 3 and 12 months post-randomization
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Time frame: At 3, 6, and 12 months post-randomization
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Time frame: At 3, 6, and 12 months post-randomization
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Time frame: At 3, 6, and 12 months post-randomization
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Time frame: Up to 12 months post-randomization
Contact information is provided by the study sponsor or research team.
Fred Hutchinson Cancer Center
Other
QuitQuest: Full Scale Randomized Trial of a Novel Smartphone Application to Help Teens Stop Vaping (QuitQuest Vaping R01)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07503925
Tobacco-Related Carcinoma
Columbus, Ohio, United States
View Trial DetailsNCT07581041
Tobacco-Related Carcinoma
Columbus, Ohio, United States
View Trial DetailsNCT06909500
Chemically-Induced Disorders, Mental Disorders
Seattle, Washington, United States
View Trial DetailsNCT07702435
Tobacco-Related Carcinoma
Columbus, Ohio, United States
View Trial Details